Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APSTZD
- Development stage
- Phase 2
- Lead developer
- Apsen Farmacêutica
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**APSTZD** is an investigational Apsen Farmaceutica drug candidate being evaluated for the treatment of chronic insomnia disorder. It is being studied in the randomized, double-blind, double-dummy Phase II TINA trial, which compares four APSTZD treatment arms with zolpidem extended-release and placebo over six weeks. The publicly available trial record does not disclose APSTZD's chemical identity, molecular target, or pharmacologic mechanism; it should therefore be treated as a distinct sponsor-coded investigational asset rather than mapped to zolpidem or another established hypnotic.
- Other names
- trazodone
02
Targets
HTR2A (Serotonin receptor 5-HT2A)ADRA1A (α1A)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on APSTZD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APSTZD.